ArticleFrontiers in aging neuroscience2026
Serum BP180 and BP230 autoantibodies in Alzheimer's disease: diagnostic and cognitive associations in a retrospective study.
Article in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To assess the prevalence and diagnostic value of serum anti-BP180 and anti-BP230 antibodies in Alzheimer's Disease (AD) and their relationship with cognitive function. Methods: We conducted a retrospective case-control study comprising 279 participants, including patients with clinically diagnosed AD and neurologically healthy controls, who were consecutively enrolled at the Third People's Hospital, Hangzhou, China, between 2022 and 2024. Serum levels of anti-BP180 and anti-BP230 antibodies were quantified using enzyme-linked immunosorbent assays (ELISAs). Among patients with AD, the relationship between cognitive function, assessed by the Mini-Mental State Examination (MMSE), and serum antibody concentrations was further evaluated. Results: After adjustment for age and sex, serum BP180 levels were significantly higher in AD patients compared with healthy controls ( Conclusion: The multivariable model incorporating BP180, age, and sex demonstrated good discriminative performance in distinguishing AD patients from controls and outperformed individual biomarkers. Integrating clinical and serological markers may improve the diagnostic performance for AD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.